Related Experiment Videos
Antisense oligonucleotides to the epidermal growth factor receptor
1Department of Medicine, The Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033, USA.
Breast Cancer Research and Treatment
|April 17, 1999
Summary
Antisense oligonucleotides targeting epidermal growth factor receptor (EGFR) mRNA effectively reduced EGFR expression and protein levels. This inhibition led to significant growth reduction in ovarian cancer cells, suggesting a potential therapeutic strategy for EGFR-overexpressing cancers.
Area of Science:
- Oncology
- Molecular Biology
- Antisense Therapeutics
Background:
- Epidermal growth factor receptor (EGFR) overexpression is linked to poor prognosis in breast cancer.
- Targeting EGFR is a logical therapeutic strategy for EGFR-driven cancers.
Purpose of the Study:
- To design and evaluate antisense oligodeoxynucleotides (ASOs) targeting human EGFR mRNA.
- To assess the efficacy of ASOs and their analogs in inhibiting EGFR expression and cancer cell growth.
Main Methods:
- Three 20-mer phosphorothioate oligodeoxynucleotides were designed to target EGFR mRNA.
- ASOs and their analogs were tested on human ovarian (SKOV3) and lung (A549) carcinoma cell lines.
- Inhibition of EGFR mRNA, EGFR protein, and in vitro cell growth was measured.
Main Results:
- All tested antisense oligonucleotides inhibited the 10 kb EGFR mRNA expression (22-97%).
- The 5.6 kb EGFR mRNA band was also inhibited by most parent oligonucleotides.
- The most potent ASOs significantly reduced EGFR protein (90-98%) and inhibited SKOV3 cell growth.
Conclusions:
- Antisense oligonucleotides are effective in inhibiting EGFR mRNA and protein expression.
- Targeting EGFR mRNA with ASOs demonstrates therapeutic potential for cancers overexpressing EGFR.
- ASO-mediated EGFR inhibition resulted in significant in vitro growth inhibition of ovarian cancer cells.